Jawairya Muhammad Hussain, Saim Mahmood Khan, Haiqa Sultan, Diya Rathi, Eyob Mekonnen Woldeyohannes, Zemichael Getu Alemayehu
{"title":"The Role of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: Enhancing Post-Surgical Outcomes and Overcoming Relapse","authors":"Jawairya Muhammad Hussain, Saim Mahmood Khan, Haiqa Sultan, Diya Rathi, Eyob Mekonnen Woldeyohannes, Zemichael Getu Alemayehu","doi":"10.1002/med4.70019","DOIUrl":null,"url":null,"abstract":"<p>Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that's usually detected at an advanced stage and has a high recurrence rate despite surgical resection, making treatment challenging. Although mitotane is still the only approved treatment, its poor effectiveness has raised interest in immunotherapy with immune checkpoint inhibitors (ICIs) such as avelumab, nivolumab, and pembrolizumab. By addressing ACC's immune response, ICIs and surgery together are intended to improve post-operative results and lower recurrence.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 3","pages":"205-208"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70019","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine Advances","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/med4.70019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that's usually detected at an advanced stage and has a high recurrence rate despite surgical resection, making treatment challenging. Although mitotane is still the only approved treatment, its poor effectiveness has raised interest in immunotherapy with immune checkpoint inhibitors (ICIs) such as avelumab, nivolumab, and pembrolizumab. By addressing ACC's immune response, ICIs and surgery together are intended to improve post-operative results and lower recurrence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
